Stamper Robert, Huang Alex, Toris Carol, Qiu Mary, Gray Gerry, Garg Reena, Ianchulev Tsontcho
UCSF Department of Ophthalmology, University of California San Francisco, San Francisco, CA, USA.
Shiley Eye Institute, UCSD, San Diego, CA, USA.
Clin Ophthalmol. 2025 Aug 21;19:2859-2870. doi: 10.2147/OPTH.S538438. eCollection 2025.
A meta-analysis of over 4000 glaucoma cases over 100 years of surgical experience demonstrates that cyclodialysis surgery is effective in lowering intraocular pressure (IOP) as an uveoscleral outflow enhancing procedure.
To conduct a systematic review and meta-analysis evaluating the clinical efficacy and safety of surgical cyclodialysis in lowering intraocular pressure in glaucoma patients.
A comprehensive search of PubMed, Cochrane, Web of Science, and EMBASE identified peer-reviewed interventional studies involving surgical cyclodialysis for IOP reduction. Key outcome measures included long-term IOP control, medication burden, and adverse event incidence. The meta-analysis was registered with PROSPERO (ID: CRD42025632759).
Forty studies spanning more than a century and including 4082 eyes were analyzed. Most studies were observational and non-randomized, with 75% employing ab-externo and 25% ab-key techniques. Given the evolution of surgical techniques and populations over time, analyses accounted for heterogeneity in outcome reporting. Across all studies, the average qualified success rate was 72.3% (range: 33-97%) over follow-up periods of 6 to 132 months. Ab-interno approaches showed slightly higher efficacy and fewer complications. Durability varied, with reduced outcomes in refractory and advanced glaucoma. Complications such as hyphema, hypotony, and vision loss were infrequent. Notably, newer ab-interno techniques demonstrated improved outcomes in IOP reduction, safety, and procedural longevity.
Cyclodialysis remains a viable and effective surgical option for enhancing uveoscleral outflow in glaucoma management. While outcomes vary by patient severity and surgical technique, particularly with older methods, modern ab-interno approaches offer enhanced efficacy and safety-especially in mild to moderate cases.
一项对4000多例青光眼病例进行的超过100年手术经验的荟萃分析表明,睫状体分离术作为一种增强葡萄膜巩膜流出的手术,在降低眼压(IOP)方面是有效的。
进行一项系统评价和荟萃分析,评估手术睫状体分离术在降低青光眼患者眼压方面的临床疗效和安全性。
全面检索PubMed、Cochrane、科学网和EMBASE,确定了涉及手术睫状体分离术降低眼压的同行评审干预性研究。主要结局指标包括长期眼压控制、药物负担和不良事件发生率。该荟萃分析已在PROSPERO注册(ID:CRD42025632759)。
分析了跨越一个多世纪的40项研究,包括4082只眼。大多数研究为观察性且非随机的,75%采用外路法,25%采用内路法。考虑到手术技术和人群随时间的演变,分析考虑了结局报告中的异质性。在所有研究中,随访6至132个月期间的平均合格成功率为72.3%(范围:33 - 97%)。内路法显示出略高的疗效和更少的并发症。疗效持久性各不相同,难治性和晚期青光眼的疗效有所降低。前房积血、低眼压和视力丧失等并发症并不常见。值得注意的是,更新的内路技术在降低眼压、安全性和手术持久性方面显示出更好的效果。
睫状体分离术仍然是青光眼治疗中增强葡萄膜巩膜流出的一种可行且有效的手术选择。虽然结局因患者严重程度和手术技术而异,特别是较老的方法,但现代内路法提供了更高的疗效和安全性,尤其是在轻至中度病例中。